Raymond Shelton
Ophthalmology · Menifee, CANPI 1679514707
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,488 of the $127,108 with a category attached, or 68.8%. 23 manufacturers reported payments, led by AbbVie at 54.5% of the total. Reporting peaked in 2019 at $50,074 and has fallen 97.3% since, to $1,355 in 2025. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 408 payments — averaging $311.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$69K
- Sun Pharmaceutical Industries Inc.$19K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$12K
- Kala Pharmaceuticals, Inc.$10K
- Johnson & Johnson Surgical Vision, Inc.$8K
- Glaukos Corporation$2K
- plus $6K from 17 others
What the payments were for
- Consulting fees$6,8005%
- Speaking & faculty fees$87,48869%
- Travel & lodging$14,43811%
- Food & beverage$17,82414%
- Entertainment$5590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $69,242 |
| Sun Pharmaceutical Industries Inc. | 41 | $19,049 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 21 | $12,210 |
| Kala Pharmaceuticals, Inc. | 25 | $9,743 |
| Johnson & Johnson Surgical Vision, Inc. | 44 | $7,968 |
| Glaukos Corporation | 24 | $2,478 |
| Alcon | 29 | $2,065 |
| Novartis | 28 | $856 |
| Optos, Inc. | 5 | $559 |
| Eyepoint US, Inc. | 5 | $444 |
| Bausch & Lomb Americas Inc. | 5 | $444 |
| Ocular Therapeutix, Inc. | 5 | $388 |
| Ivantis, Inc | 5 | $377 |
| Shire North American Group Inc | 7 | $309 |
| Amgen(2 entities) | 3 | $270 |
| Eyevance Pharmaceuticals LLC | 7 | $261 |
| Nova Eye, Inc. | 1 | $138 |
| Eagle Pharmaceuticals, Inc. | 1 | $127 |
| Sight Sciences, Inc. | 1 | $75 |
| Rxsight Inc | 2 | $46 |
| Oyster Point Pharma, Inc. | 1 | $26 |
| Omeros Corporation | 1 | $20 |
| Tearlab Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RESTASIS$50,298
- RESTASIS MULTIDOSE$17,153
- CEQUA$14,635
- LOTEMAX SM$7,606
- INVELTYS$5,262
- EYSUVIS$5,198
- Tecnis Multifocal Family of 1-piece IOLS$4,770
- BROMSITE$4,191
- PROLENSA$4,156
- Tecnis Symfony IOL$1,580
- Tecnis Symfony Toric IOL$1,467
- Tecnis 1-piece IOL$1,357
- Tecnis 3-piece IOL$1,357
- iStent inject Trabecular Micro-Bypass Stent System$630
- XELPROS$569
- P200DTx$521
- P200T$521
- P200TE$521
- P200TxE$521
- iStent infinite Trabecular Micro-Bypass System Model iS3$409
How this compares
$127,108 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 54 | $50,595 |
| LumiganBimatoprost | 48 | $24,423 |
| Prednisolone Acetate | 742 | $21,989 |
| Cyclosporine | 57 | $20,591 |
| RocklatanNetarsudil Mesylat/Latanoprost | 42 | $16,286 |
| MoxifloxacinMoxifloxacin Hcl | 558 | $15,429 |
| Alphagan PBrimonidine Tartrate | 43 | $11,098 |
| VyzultaLatanoprostene Bunod | 38 | $10,172 |
| Ketorolac Tromethamine | 633 | $9,888 |
| Latanoprost | 602 | $5,901 |
| RhopressaNetarsudil Mesylate | 14 | $5,550 |
| Brimonidine Tartrate | 174 | $5,187 |
| Fluorometholone | 59 | $4,746 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 211 | $4,369 |
| Loteprednol Etabonate | 20 | $4,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $69,242 | $86,116145 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $444 | $10,17238 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $12,210 | $4,00420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Menifee
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
- Savak TeymoorianLaguna Hills$955K
- Andrew MoshfeghiLos Angeles$895K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.